domingo, 2 de noviembre de 2014

Genomics|Genetic Testing|Tier 3

Genomics|Genetic Testing|Tier 3

Genetic Testing

Genomic Tests and Family History by Levels of Evidence

The CDC Office of Public Health Genomics ranks the following list for levels of evidence of genomic tests and family health history in practice . This approach was based on a paper by KhouryExternal Web Site Icon and updated in accordance with criteria presented by a 2014 paper in Clinical Pharmacology and TherapeuticsExternal Web Site Icon. The criteria are  shown in the following figure to provide additional information to our readers. This list is updated on an ongoing basis andprovided only for informational purposes to researchers, healthcare providers, public health programs and others.
  • FDA label requires use of test to inform choice or dose of a drug
  • CMS covers testing
  • Clinical practice guidelines based on systematic review supports testing

  • FDA label mentions biomarkers*
  • CMS coverage with evidence development
  • Clinical practice guideline, not based on systematic review, supports use of test
  • Clinical practice guideline finds insufficient evidence but does not discourage use of test
  • Systematic review, without clinical practice guideline, supports use of test
  • Systematic review finds insufficient evidence but does not discourage use of test
  • Clinical practice guideline recommends dosage adjustment, but does not address testing

  • FDA label cautions against use
  • CMS decision against coverage
  • Clinical practice guideline recommends against use of test
  • Clinical practice guideline finds insufficient evidence and discourages use of test
  • Systematic review recommends against use
  • Systematic review finds insufficient evidence and discourages use
  • Evidence available only from published studies without systematic reviews, clinical practice guidelines, FDA label or CMS labels coverage decision
*Can be reassigned to Green of Red of one or more conditions in these categories apply 

Tier 3/Red category: represents genomic and family health history applications either have synthesized evidence culminating in recommendations against use (or discouraging use), OR no relevant synthesized evidence was identified. Such applications are not ready for routine practice, but may be considered in clinical and population research.

Gene, Gene/Drug, Test, or Family HistoryDisorder/IndicationUse*Synthesized Evidence Sources
HFEhereditary hemochromatosispopulation screeningUSPSTFExternal Web Site Icon (2006)
routine BRCA genetic counseling, routine BRCA testingHereditary breast/ovarian cancer, in women whose family history is not associated with an increased risk of BRCA mutationspopulation screeningUSPSTFExternal Web Site Icon (2013)
panels for various genetic risk factorscommon diseasesrisk assessment, disease preventionMultiple sources, for example:EGAPPExternal Web Site Icon (2010)
next generation sequencing/whole genome sequencevarious common diseasesrisk predictionRapidly evolving landscape; gaps in knowledge exist for analytic validity, clinical validity and clinical utility
SNP panelstype 2 diabetesrisk predictionEGAPP Adobe PDF file [PDF 242.05 KB]External Web Site Icon (2013)
TCF7L2 genotypingtype 2 diabetesrisk predictionEGAPP Adobe PDF file [PDF 242.05 KB]External Web Site Icon (2013)
NRAS or PIK3CA mutation analysis and/or testing for loss of PTEN or AKT protein expression/anti-EGFR therapymetastatic colorectal cancerPGx
CYP450 testing/SSRIsnon-psychotic depressionPGx, PGx-doseEGAPPExternal Web Site Icon (2007)
tumor gene expression analysis (Prolaris®, Oncotype Dx® Prostateprostate cancerprognostic, managementBCBS TECExternal Web Site Icon (2014)
emerging genomic tests in the CDC'sGAPP FinderExternal Web Site Icon of theGAPP Knowledge BaseExternal Web Site Iconvarious disordersvarious usesAlmost all of these applications (except when listed above) have insufficient information on analytic or clinical validity, or clinical utility

*Pharmacogenomic applications have been classified in the Use column as either PGx (which may relate to drug choice, prevention of adverse events, or other uses of the information gained through testing), or PGx-dose (when specific dosing-related guidance is provided, or mention of a potential effect on dose is noted in the evidence sources cited). Additional Use categories include: screening, cascade testing, risk prediction, diagnostic, and prognostic.
Source Abbreviations: Agency for Healthcare Research and Quality (AHRQ), American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), Centers for Medicare and Medicaid Services (CMS), Clinical Pharmacogenetics Implementation Consortium (CPIC), Evaluation of Genomic Applications in Practice and Prevention (EGAPP), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), National Institutes of Health (NIH), Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), US Department of Health and Human Services (DHHS), US Food and Drug Administration (FDA), United States Preventive Services Task Force (USPSTF)
Other Abbreviations: estrogen receptor (ER), progesterone receptor (PgR), pharmacogenomics (PGx), single-nucleotide polymorphism (SNP)

No hay comentarios:

Publicar un comentario